6533b873fe1ef96bd12d5787

RESEARCH PRODUCT

Additional file 1: of Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga]Ga-DATA-TOC

Jean-philippe SinnesJohannes NagelBradley WaldronTheodosia MainaBerthold NockRalf BergmannMartin UllrichJens PietzschMichael BachmannRichard BaumFrank Rösch

subject

description

Table S1. Binding affinities of [natGa]Ga-DATA-TOC and [natGa]Ga-DOTA-TOC on hSST2/3/5, as determined during displacement of [125I-Tyr25]LTT-SS28 from transfected HEK293-hSST2/3/5 cell membranes; LTT-SS28 served as reference. Table S2. Uptake in terms of %IA of [68Ga]Ga-DATA-TOC or [68Ga]Ga-DOTA-TOC in selected organs of MPC-mCherry tumour-bearing female NMRI nu/nu mice 1 h p.i. (218 ± 57 MBq (11.2 nmol peptide/kg) and 441 ± 109 MBq (10.5 nmol peptide)/kg body weight, respectively; blocking after coinjection of 100 µg/mouse [Nal3]octreotide acetate)). Table S3. Radioactivity concentration in terms of SUV of [68Ga]Ga-DATA-TOC or [68Ga]Ga-DOTA-TOC in selected organs of MPC-mCherry tumour-bearing female NMRI nu/nu mice 1 h p.i. (218 ± 57 MBq (11.2 nmol peptide/kg) and 441 ± 109 MBq (10.5 nmol peptide)/kg body weight, respectively; blocking after coinjection of 100 µg/mouse [Nal3]octreotide acetate)). Figure S1. (A) Cyclic chelators used for 68Ga: DOTA, NOTA, TRAP and (B) acyclic chelators used for 68Ga: DFO, DTPA, HDEB, and a bifunctional version of THP. (DOCX 104 kb)

https://dx.doi.org/10.6084/m9.figshare.8180102